Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

Sattva S. Neelapu, Larry W. Kwak, Carol B. Kobrin, Craig W. Reynolds, John Edward Janik, Kieron Dunleavy, Therese White, Linda Harvey, Robin Pennington, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Seth M. Steinberg, Ronald Gress, Fran Hakim, Wyndham H. Wilson

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The role of B cells in T-cell priming is unclear, and the effects of B-cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell-dependent immunity by competing with antigen-presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/or inducing T-cell tolerance, results from others suggest that B cells are necessary for priming as well as generation of T-cell memory. We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor-specific responses were detectable but delayed, and they correlated with peripheral blood B-cell recovery. In contrast, vigorous CD4+ and CD8+ antitumor type I T-cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B-cell depletion does not impair T-cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses.

Original languageEnglish (US)
Pages (from-to)986-991
Number of pages6
JournalNature Medicine
Volume11
Issue number9
DOIs
StatePublished - Sep 1 2005

Fingerprint

Mantle-Cell Lymphoma
Cancer Vaccines
Tumors
Immunity
T-cells
B-Lymphocytes
Vaccines
Cells
T-Lymphocytes
Recovery
Chemotherapy
Viral Tumor Antigens
Neoplasm Antigens
Antigen-Presenting Cells
Blood Cells
Blood
Cytokines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Neelapu, S. S., Kwak, L. W., Kobrin, C. B., Reynolds, C. W., Janik, J. E., Dunleavy, K., ... Wilson, W. H. (2005). Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 11(9), 986-991. https://doi.org/10.1038/nm1290

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. / Neelapu, Sattva S.; Kwak, Larry W.; Kobrin, Carol B.; Reynolds, Craig W.; Janik, John Edward; Dunleavy, Kieron; White, Therese; Harvey, Linda; Pennington, Robin; Stetler-Stevenson, Maryalice; Jaffe, Elaine S.; Steinberg, Seth M.; Gress, Ronald; Hakim, Fran; Wilson, Wyndham H.

In: Nature Medicine, Vol. 11, No. 9, 01.09.2005, p. 986-991.

Research output: Contribution to journalArticle

Neelapu, SS, Kwak, LW, Kobrin, CB, Reynolds, CW, Janik, JE, Dunleavy, K, White, T, Harvey, L, Pennington, R, Stetler-Stevenson, M, Jaffe, ES, Steinberg, SM, Gress, R, Hakim, F & Wilson, WH 2005, 'Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma', Nature Medicine, vol. 11, no. 9, pp. 986-991. https://doi.org/10.1038/nm1290
Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine. 2005 Sep 1;11(9):986-991. https://doi.org/10.1038/nm1290
Neelapu, Sattva S. ; Kwak, Larry W. ; Kobrin, Carol B. ; Reynolds, Craig W. ; Janik, John Edward ; Dunleavy, Kieron ; White, Therese ; Harvey, Linda ; Pennington, Robin ; Stetler-Stevenson, Maryalice ; Jaffe, Elaine S. ; Steinberg, Seth M. ; Gress, Ronald ; Hakim, Fran ; Wilson, Wyndham H. / Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. In: Nature Medicine. 2005 ; Vol. 11, No. 9. pp. 986-991.
@article{f778eee436d64b689bc91d872158cc57,
title = "Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma",
abstract = "The role of B cells in T-cell priming is unclear, and the effects of B-cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell-dependent immunity by competing with antigen-presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/or inducing T-cell tolerance, results from others suggest that B cells are necessary for priming as well as generation of T-cell memory. We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor-specific responses were detectable but delayed, and they correlated with peripheral blood B-cell recovery. In contrast, vigorous CD4+ and CD8+ antitumor type I T-cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B-cell depletion does not impair T-cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses.",
author = "Neelapu, {Sattva S.} and Kwak, {Larry W.} and Kobrin, {Carol B.} and Reynolds, {Craig W.} and Janik, {John Edward} and Kieron Dunleavy and Therese White and Linda Harvey and Robin Pennington and Maryalice Stetler-Stevenson and Jaffe, {Elaine S.} and Steinberg, {Seth M.} and Ronald Gress and Fran Hakim and Wilson, {Wyndham H.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1038/nm1290",
language = "English (US)",
volume = "11",
pages = "986--991",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

AU - Neelapu, Sattva S.

AU - Kwak, Larry W.

AU - Kobrin, Carol B.

AU - Reynolds, Craig W.

AU - Janik, John Edward

AU - Dunleavy, Kieron

AU - White, Therese

AU - Harvey, Linda

AU - Pennington, Robin

AU - Stetler-Stevenson, Maryalice

AU - Jaffe, Elaine S.

AU - Steinberg, Seth M.

AU - Gress, Ronald

AU - Hakim, Fran

AU - Wilson, Wyndham H.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The role of B cells in T-cell priming is unclear, and the effects of B-cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell-dependent immunity by competing with antigen-presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/or inducing T-cell tolerance, results from others suggest that B cells are necessary for priming as well as generation of T-cell memory. We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor-specific responses were detectable but delayed, and they correlated with peripheral blood B-cell recovery. In contrast, vigorous CD4+ and CD8+ antitumor type I T-cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B-cell depletion does not impair T-cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses.

AB - The role of B cells in T-cell priming is unclear, and the effects of B-cell depletion on immune responses to cancer vaccines are unknown. Although results from some mouse models suggest that B cells may inhibit induction of T cell-dependent immunity by competing with antigen-presenting cells for antigens, skewing T helper response toward a T helper 2 profile and/or inducing T-cell tolerance, results from others suggest that B cells are necessary for priming as well as generation of T-cell memory. We assessed immune responses to a well-characterized idiotype vaccine in individuals with severe B-cell depletion but normal T cells after CD20-specific antibody-based chemotherapy of mantle cell lymphoma in first remission. Humoral antigen- and tumor-specific responses were detectable but delayed, and they correlated with peripheral blood B-cell recovery. In contrast, vigorous CD4+ and CD8+ antitumor type I T-cell cytokine responses were induced in most individuals in the absence of circulating B cells. Analysis of relapsing tumors showed no mutations or change in expression of target antigen to explain escape from therapy. These results show that severe B-cell depletion does not impair T-cell priming in humans. Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses.

UR - http://www.scopus.com/inward/record.url?scp=24744457075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744457075&partnerID=8YFLogxK

U2 - 10.1038/nm1290

DO - 10.1038/nm1290

M3 - Article

VL - 11

SP - 986

EP - 991

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -